These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30315150)

  • 1. N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial.
    Klauser P; Xin L; Fournier M; Griffa A; Cleusix M; Jenni R; Cuenod M; Gruetter R; Hagmann P; Conus P; Baumann PS; Do KQ
    Transl Psychiatry; 2018 Oct; 8(1):220. PubMed ID: 30315150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis.
    Conus P; Seidman LJ; Fournier M; Xin L; Cleusix M; Baumann PS; Ferrari C; Cousins A; Alameda L; Gholam-Rezaee M; Golay P; Jenni R; Woo TW; Keshavan MS; Eap CB; Wojcik J; Cuenod M; Buclin T; Gruetter R; Do KQ
    Schizophr Bull; 2018 Feb; 44(2):317-327. PubMed ID: 29462456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment in early psychosis with N-acetyl-cysteine for 6months improves low-level auditory processing: Pilot study.
    Retsa C; Knebel JF; Geiser E; Ferrari C; Jenni R; Fournier M; Alameda L; Baumann PS; Clarke S; Conus P; Do KQ; Murray MM
    Schizophr Res; 2018 Jan; 191():80-86. PubMed ID: 28711476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial.
    Voineskos AN; Mulsant BH; Dickie EW; Neufeld NH; Rothschild AJ; Whyte EM; Meyers BS; Alexopoulos GS; Hoptman MJ; Lerch JP; Flint AJ
    JAMA Psychiatry; 2020 Jul; 77(7):674-683. PubMed ID: 32101271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired fornix-hippocampus integrity is linked to peripheral glutathione peroxidase in early psychosis.
    Baumann PS; Griffa A; Fournier M; Golay P; Ferrari C; Alameda L; Cuenod M; Thiran JP; Hagmann P; Do KQ; Conus P
    Transl Psychiatry; 2016 Jul; 6(7):e859. PubMed ID: 27459724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders.
    Breier A; Liffick E; Hummer TA; Vohs JL; Yang Z; Mehdiyoun NF; Visco AC; Metzler E; Zhang Y; Francis MM
    Schizophr Res; 2018 Sep; 199():395-402. PubMed ID: 29588126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis.
    Cotton SM; Berk M; Watson A; Wood S; Allott K; Bartholomeusz CF; Bortolasci CC; Walder K; O'Donoghue B; Dean OM; Chanen A; Amminger GP; McGorry PD; Burnside A; Uren J; Ratheesh A; Dodd S
    Trials; 2019 Nov; 20(1):658. PubMed ID: 31779696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimodal prevention of first psychotic episode through N-acetyl-l-cysteine and integrated preventive psychological intervention in individuals clinically at high risk for psychosis: Protocol of a randomized, placebo-controlled, parallel-group trial.
    Schmidt SJ; Hurlemann R; Schultz J; Wasserthal S; Kloss C; Maier W; Meyer-Lindenberg A; Hellmich M; Muthesius-Digón A; Pantel T; Wiesner PS; Klosterkötter J; Ruhrmann S;
    Early Interv Psychiatry; 2019 Dec; 13(6):1404-1415. PubMed ID: 30784233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Acetyl-Cysteine Supplementation Improves Functional Connectivity Within the Cingulate Cortex in Early Psychosis: A Pilot Study.
    Mullier E; Roine T; Griffa A; Xin L; Baumann PS; Klauser P; Cleusix M; Jenni R; Alemàn-Gómez Y; Gruetter R; Conus P; Do KQ; Hagmann P
    Int J Neuropsychopharmacol; 2019 Aug; 22(8):478-487. PubMed ID: 31283822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial.
    Sepehrmanesh Z; Heidary M; Akasheh N; Akbari H; Heidary M
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Mar; 82():289-296. PubMed ID: 29126981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-Acetylcysteine effects on glutathione and glutamate in schizophrenia: A preliminary MRS study.
    Yang YS; Maddock RJ; Zhang H; Lee J; Hellemann G; Marder SR; Green MF
    Psychiatry Res Neuroimaging; 2022 Sep; 325():111515. PubMed ID: 35839558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. White matter correlates of episodic memory encoding and retrieval in schizophrenia.
    Green AE; Croft RJ; Maller JJ; Fitzgerald PB
    Psychiatry Res Neuroimaging; 2016 Aug; 254():188-98. PubMed ID: 27479923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms.
    Rossell SL; Francis PS; Galletly C; Harris A; Siskind D; Berk M; Bozaoglu K; Dark F; Dean O; Liu D; Meyer D; Neill E; Phillipou A; Sarris J; Castle DJ
    BMC Psychiatry; 2016 Sep; 16(1):320. PubMed ID: 27629871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study.
    Takiguchi K; Uezato A; Itasaka M; Atsuta H; Narushima K; Yamamoto N; Kurumaji A; Tomita M; Oshima K; Shoda K; Tamaru M; Nakataki M; Okazaki M; Ishiwata S; Ishiwata Y; Yasuhara M; Arima K; Ohmori T; Nishikawa T
    BMC Psychiatry; 2017 Jul; 17(1):249. PubMed ID: 28701225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal white matter microstructure in drug-naive first episode schizophrenia patients before and after eight weeks of antipsychotic treatment.
    Zeng B; Ardekani BA; Tang Y; Zhang T; Zhao S; Cui H; Fan X; Zhuo K; Li C; Xu Y; Goff DC; Wang J
    Schizophr Res; 2016 Apr; 172(1-3):1-8. PubMed ID: 26852402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. White matter changes associated with antipsychotic treatment in first-episode psychosis.
    Szeszko PR; Robinson DG; Ikuta T; Peters BD; Gallego JA; Kane J; Malhotra AK
    Neuropsychopharmacology; 2014 May; 39(6):1324-31. PubMed ID: 24549105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.
    Farokhnia M; Azarkolah A; Adinehfar F; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Sadeghi SM; Moghadam M; Gharibi F; Mirshafiee O; Akhondzadeh S
    Clin Neuropharmacol; 2013; 36(6):185-92. PubMed ID: 24201233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.
    Yang C; Bosker FJ; Li J; Schoevers RA
    BMC Psychiatry; 2018 Sep; 18(1):279. PubMed ID: 30176835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial.
    Bloch MH; Panza KE; Yaffa A; Alvarenga PG; Jakubovski E; Mulqueen JM; Landeros-Weisenberger A; Leckman JF
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):327-34. PubMed ID: 27027204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness of N-acetylcysteine in the treatment of schizophrenia].
    Miyake N; Miyamoto S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2016 Apr; 36(2):29-35. PubMed ID: 27333656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.